A Clinical Study: Rosiglitazone Treats The Patients With Polycystic Ovary Syndrome

Objective: We have studied the therapeutic effects of rosiglitazone on polycystic ovary syndrome and observed the changes of reproductive hormones and the resumption of ovulation and menses so as to explore its clinical significance in treatment of insulin resistance of PCOS patients.Methods: 30 patients with the diagnosis of PCOS and the level of insulin larger than 15.6uIU/ml took 4mg of rosiglitazone everyday morning for a consecutive period of 12 weeks and the comparison of body mass index, ratio of waist to hip, insulin level, blood glucose level, insulin resistance index, leptin, reproductive hormones and ovulation rate was made.Results: Basal insulin, fasting plasma glucose, blood glucose 2 hours postprandial meal, insulin resistance index, leptin, testosterone, free testerone, dehydroepiandrosterone sulfate, leutinizing hormone and the ratio of LH/FSH decreased significantly while sex hormone binding protein increased significantly after treatment for 12 weeks.Conclusion: rosiglitazone has increased the tissue sensitivity to insulin, decreased the leptin level, modified sugar metabolism disturbance and hyperandrogenism and improved the resumption of ovulation, suggesting some clinical implications.